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Several known hereditary cancer syndromes confer an increased risk for genitourinary 
(GU)related malignancies. Various guidelines indicate when to refer patients to genetic 
counseling for GU-related hereditary cancer syndromes but there is limited research on the 
clinical picture of these patients, including their cancerous and non-cancerous features, the 
genetic testing strategy for this population, and the probability of having a positive germline 
mutation if testing is performed. The purpose of this study is to determine the most common 
indications for ordering genetic testing in a GU Genetics Clinic and evaluate whether there is a 
relationship between the indication for genetic testing and genetic testing outcome. An 
institutional review board-approved retrospective chart review was performed for 220 patients 
seen in the GU Genetics Clinic at M.D. Anderson Cancer Center. Patients were stratified into 
groups based on their indication for genetic testing and an exact binomial test was used to 
compare the proportion of patients with a positive genetic test from various groups. The 
majority of patients (92%) were seen for genetic evaluation related to either renal cell 
carcinoma (RCC) or prostate cancer. Among patients seen for RCC-related evaluation (N=107), 
meeting published clinical criteria for a hereditary RCC syndrome significantly predicted 
positive genetic testing (P<0.001). No other indication for testing, including early onset RCC 
(diagnosed ≤ 46 years) predicted for positive genetic test results. Among patients seen for 
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prostate-related evaluation (N=101), 7 individuals tested positive for a hereditary syndrome 
related to prostate cancer, however none were identified by metastatic prostate cancer status 
alone. Our data suggest current algorithms lack sensitivity for selecting individuals with RCC or 
prostate cancer at risk for germline mutations. Evaluation of pedigree and identifying presence 
of syndromic features can guide risk assessment and increase the probability of identifying 
individuals with GU cancers at risk for harboring a germline cancer causing mutation.   
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INTRODUCTION 
Cancers of the genitourinary (GU) system include prostate, renal, urinary tract, testicular, and 
bladder cancer. The known hereditary components and the relatively high incidence of particular 
GU cancers make them a relevant subset of cancers in the setting of a genetic evaluation.  Prostate 
cancer is the most common cancer diagnosis in men in the United States (1). It is estimated that 5-
10% of prostate cancers are due to inherited pathogenic variants in highly penetrant or moderately 
penetrant genes (2). Aggressive cases of prostate cancer, in particular, have a higher association 
with an inherited predisposition, with 11.8% of metastatic prostate cancers resulting from a 
pathogenic germline variant in DNA- damage repair (DDR) genes (3). Renal cancer is similarly 
known to be associated with inherited pathogenic variants. Conservative estimates predict that 5% 
to 8% of renal cell carcinoma (RCC) is hereditary (4). 
Several known hereditary cancer syndromes confer an increased risk for GU-related 
malignancies. Pathogenic variants in BRCA1 and BRCA2, causing Hereditary Breast and Ovarian 
Cancer syndrome (HBOC), make up over 50% of the pathogenic variants found in DDR genes 
among men with metastatic prostate cancer (3). The National Comprehensive Cancer Network 
(NCCN) Genetic/Familial High-Risk Assessment- Breast and Ovarian Guidelines provide criteria 
for when to evaluate patients for HBOC. These guidelines consider both personal and family history 
of prostate cancer, especially when combined with cases of breast and/or ovarian cancer in a family 
(5).  Just as HBOC causes hereditary cases of prostate cancer, at least eight different syndromes 
predispose to RCC including von Hippel-Lindau (VHL) disease, hereditary papillary renal 
carcinoma (HPRC), Birt-Hogg-Dube syndrome (BHD), hereditary leiomyomatosis and renal cell 
carcinoma (HLRCC), succinate dehydrogenase-deficient kidney cancer, Tuberous Sclerosis 
Complex (TSC), BAP1-associated tumor predisposition syndrome, and MiTF-associated cancer 
syndrome (6).  Some of these syndromes are highly associated with non-cancerous features that aid 
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in the identification of affected individuals. VHL disease is associated with a high penetrance for 
retinal and central nervous system hemangioblastomas in addition to clear cell renal cell carcinoma 
(ccRCC) (7-9). Individuals with HLRCC present with multiple or symptomatic leiomyomas and 
early onset type 2 papillary RCC (10). Fibrofolliculomas and spontaneous pneumothoraces are 
indicative of BHD (11). TSC has a very well- defined phenotypic presentation with multiple major 
and minor features contributing to a clinical diagnosis (12) .   
Many indications may warrant a genetic evaluation for patients with GU cancers. Practice 
guidelines published by the American College of Medical Genetics and Genomics (ACMG) and the 
National Society of Genetic Counselors (NSGC) support that referral of GU cancer patients for a 
genetics consultation is indicated in the context of both personal and family history. The 
ACMG/NSGC guidelines for RCC patients encompass high-risk factors such as bilateral or 
multifocal ccRCC, ccRCC in the context of a family history of ccRCC, renal tumor histology 
suggestive of a hereditary syndrome (e.g. any papillary type II RCC being suggestive of HLRCC), 
upper tract urothelial carcinoma (UTUC) in the context of a family history of Lynch syndrome 
associated cancers, and RCC in the context of other RCC-related syndromic features. The 
ACMG/NSGC guidelines for prostate cancer include high-risk factors such as family history of 
prostate cancer in first degree relatives, family history of early onset prostate cancer, and aggressive 
(Gleason score>7) prostate cancer in the context of a family history of breast, ovarian, or pancreatic 
cancer (13). Published research also suggests that genetic counseling or consideration of germline 
testing is indicated for some individuals, despite the absence of non-cancerous findings and/or 
family history, due to factors that put them at an increased risk for a hereditary cancer 
predisposition. One of these high-risk factors is RCC diagnosed ≤46 years old, as early onset RCC 
may be a sign of a hereditary syndrome (4). Another high-risk factor in the setting of GU cancers is 
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metastatic prostate cancer. Recent research suggests that all men with metastatic prostate cancer 
should undergo germline genetic testing of DDR genes (3, 14). 
Multiple studies on genetic testing outcomes of RCC patients suggest that early onset RCC is a 
significant predictor of positive genetic testing (15, 16). Other factors believed to predict positive 
genetic test results are non-cancerous manifestations of RCC syndromes and multiple primary renal 
tumors. The significance of family history of RCC in predicting at-risk individuals has been 
questioned (15, 16). Studies of genetic testing outcomes in men with prostate cancer support that 
those meeting NCCN guidelines for HBOC testing are at the highest risk for mutations  yet 
recognize that many men perceived to have a hereditary prostate cancer may not have an 
identifiable gene mutation (14). The literature effectively describes when to refer patients for 
genetic counseling for GU-related hereditary cancer syndromes, however there is limited research 
on the clinical picture of these patients, including their cancerous and non-cancerous features and 
indications for genetic testing (3-5, 13). Previous studies of this population have not commented on 
whether individual indications, independent of one another, predict positive germline testing. 
Additionally, the genetic testing strategy and decision-making process in a GU genetics clinic has 
not been described.  
This study aims to assess the most common indications for ordering genetic testing in a GU 
setting. Additionally, the study aims to evaluate whether there is a relationship between the 
indication for genetic testing and genetic testing outcome. To do so, a retrospective chart review 
was conducted of test results and clinical data from patients seen for genetic counseling in the 
Genitourinary Genetics Clinic at The University of Texas M.D. Anderson Cancer Center. 
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METHODS 
Institutional Review Board approval was obtained for a retrospective chart review of 220 
patients seen for genetic counseling at M.D. Anderson Cancer Center’s Genitourinary Genetics 
Clinic between July 1, 2014 and June 30, 2017. All patients had either a personal history of a GU 
cancer (RCC, prostate, UTUC, testicular, or bladder), family history of GU cancer(s), personal 
history of non-cancerous findings suggestive of a GU-related hereditary cancer syndrome, or family 
history of a germline pathogenic variant in a gene causing a hereditary cancer syndrome. GU-
related hereditary cancer syndromes with non-cancerous findings considered in this study include 
BHD, HLRCC, VHL disease, and TSC, as these syndromes have published clinical diagnostic 
criteria. All patients in this clinic underwent genetic counseling and formal genetic assessment for 
hereditary cancer syndromes including potential evaluation of both benign and malignant features. 
As part of the genetic counseling process, a three generation pedigree was obtained for each patient 
to evaluate cancer histories in the family. 
 Each patient’s medical and family histories were assessed to determine whether genetic 
testing was indicated based on published literature and whether genetic testing was ordered. 
Assessment of family history included reviewing each patient’s pedigree in order to determine the 
family’s cancer history and familial RCC or familial prostate cancer status (defined as two or more 
relatives of the same lineage, not including the patient, with the same type of cancer) (17). When 
applicable, the type of genetic testing ordered and result of genetic testing were recorded.  
Genetic testing was considered to be indicted based on personal history if the patient had 
any of the following: a clinical diagnosis of VHL disease, a clinical diagnosis of TSC , a suspected 
diagnosis of BHD, a likely or suspected diagnosis of HLRCC, early onset RCC (≤46 years), 
metastatic prostate cancer , or personal features meeting ACMG/NSCG Practice Guidelines for 
referral to genetic counseling for prostate or renal cancer (henceforth known as ACMG/NSGC 
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guidelines). ACMG/NSGC guidelines indicate only when patients should be referred for a genetic 
counseling evaluation, not when to order genetic testing. However, in the context of limited 
guidelines for genetic testing in the GU cancer population, this study evaluated ACMG/NSGC 
guidelines as if they were an indication for genetic testing. Genetic testing was considered to be 
indicted based on family history if the patient had any of the following: a reported familial germline 
pathogenic variant in a gene causing a hereditary cancer syndrome, family history meeting NCCN 
BRCA-Related Breast and Ovarian Cancer Syndrome testing criteria (versions 1.2014- 2.2017), or 
family history meeting ACMG/NSCG guidelines. For each patient, the specific version of NCCN 
BRCA-Related Breast and Ovarian Cancer Syndrome guidelines valid at the time of their genetic 
counseling consultation was considered. 
 Genetic testing type was categorized as single site, single syndrome, or panel testing. Single 
syndrome genetic testing may have included testing more than one gene related to a given 
syndrome, such as testing both BRCA1 and BRCA2 under the category of HBOC. Genetic testing 
results were recorded as positive, negative, variant of uncertain significance (VUS)- likely 
pathogenic, VUS, and VUS-likely benign. “Positive” genetic testing henceforth includes both 
positive and VUS-likely pathogenic results in order to mimic the treatment of these results in a 
clinical setting. Similarly, “negative” testing includes negative and VUS-likely benign results. In 
this population, true VUS results did not change medical management for any patients. Therefore, 
patients with VUS results from germline testing were categorized with the negative group during 
the evaluation of the relationship between indication for testing and genetic testing outcome. Tables 
where VUS results have been included in the negative category are indicated as such.  
The total population was stratified into three groups: 1) patients seen for genetic evaluation 
of hereditary cancer syndromes related to RCC, 2) patients seen for genetic evaluation of hereditary 
cancer syndromes related to prostate cancer, and 3) patients seen for genetic evaluation of other GU 
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cancers. These groups were not mutually exclusive as some patients were seen for evaluation of 
both renal and prostate cancer and were included in both groups.  
 Patients were stratified by indication for genetic testing and the rate of positive genetic test 
results was reported for each group. The statistical relationship between indication for genetic 
testing and genetic testing outcome was determined using the Pearson chi-square and exact chi-
square tests with P<0.05 considered to be statistically significant. Statistical analysis was performed 
using STATA/IC version 13.1 (StataCorp, College Station, TX) and SAS version 9.4 (SAS 
Institute, Cary, NC). All tests of statistical significance utilized SAS.  
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RESULTS 
A total of 220 patients were seen for genetic counseling in the GU Genetics Clinic between 
July 1, 2014 and June 30, 2017. All 220 patients were included in this study. The majority of the 
population was Caucasian (76%) and 4% reported Ashkenazi Jewish ancestry. Population 
demographics are summarized in Table 1. A total of 201 patients (91%) had a diagnosis of cancer 
Table 1  Demographic Information 
 
Characteristic Frequency Percent Cumulative 
Sex    
Male 169 23.18 23.18 
Female 51 76.82 100.00 
Ethnicity    
Hispanic or Latino 34 15.45 15.45 
Not Hispanic or Latino 179 81.36 96.82 
Unknown 7 3.18 100.00 
Race    
White or Caucasian 166 75.45 75.45 
Black or African American 13 5.91 81.36 
Asian 9 4.09 85.45 
Other 24 10.91 96.36 
Unknown 8 3.64 100.00 
Ashkenazi Ethnicity    
Ashkenazi 8 3.64 3.64 
Not Ashkenazi 212 96.36 100.00 
 
(any type) with 158 having a single cancer diagnosis, 33 having two primary cancer diagnoses, and 
10 having three or more primary cancer diagnoses. There were 86 patients (39%) with a diagnosis 
of RCC, 8 of whom had two primary diagnoses of RCC, giving a total of 94 individual RCC 
diagnoses. The average age of RCC diagnosis was 45 years old (20-72 years). The majority of 
RCCs were clear cell type (66%) followed by chromophobe, papillary type II, oncocytoma type, 
and papillary type 1. Five patients had mixed RCC histology. A total of 99 patients (45%) had a 
diagnosis of prostate cancer, of whom 56 were confirmed metastatic and 78 were aggressive 
(Gleason ≥ 7). The average age of prostate cancer diagnosis was 59 years old (41-82 years). 
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Additionally, 11 patients had UTUC, 9 patients had bladder cancer, and 1 patient had testicular 
cancer (Table 2). 
Table 2 Oncologic Information 
 
Cancer Type Frequency Percent Cumulative 
Renal cell carcinoma    
ALL 94 100.00  
Clear cell 62 65.96 65.96 
Papillary type I 3 3.19 69.15 
Papillary type II 6 6.38 75.53 
Chromophobe 7 7.45 82.98 
Oncocytoma 5 5.32 88.30 
Papillary Unspecified 6 6.38 94.68 
Mixed 5 5.32 100.00 
Prostate    
ALL 99 100.00  
Gleason score ≥ 7 78 78.79 78.79 
Gleason score <7 16 16.16 94.95 
Gleason score unknown 5 5.05 100.00 
Metastatic 56 56.67 56.67 
Not metastatic 43 43.43 100.00 
UTUC 11   
Bladder 9   
Testicular 1   
 
In total, 194 individual genetic tests were ordered for 174 patients and 27 germline 
mutations were identified (14% rate of positivity). A VUS was identified in 23 patients (12%).  The 
most common type of testing ordered was multi-gene panel testing (59%) followed by single 
syndrome (36%), and single site testing (5%). Multi-gene panel testing yielded positive results in 
9% of tests and had a VUS rate of 19%. Single syndrome testing yielded positive results in 17% of 
tests with a VUS rate of less than 1%.  
The majority of patients (203 of 220, 92%) were referred for evaluation of syndromes 
related to RCC or prostate cancer. There were 102 patients with RCC-related referrals, 96 with 
prostate-related referrals, and 5 patients seen for evaluation of both RCC and prostate-related 
hereditary cancer syndromes. In 2014 and 2015, the majority of referrals were RCC-related (83% 
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and 71% respectively). In 2016 and 2017, the majority of referrals were prostate-related (52% and 
68% respectively). 
 There were 107 patients in the RCC-related referral group (including the 5 patients with 
overlapping RCC and prostate indications). Genetic testing was ordered for 97 patients in this 
population and 16 tested positive for a hereditary cancer syndrome related to RCC. Six mutations 
were identified in the FH gene, 5 in the FLCN gene, 3 in the VHL gene, 1 in the BAP1 gene, 1 in the 
SDHB gene, and 1 in the TP53 gene. The indications for genetic testing in this group are 
summarized in Table 3. Patients may have had more than one indication for ordering genetic 
Table 3 Indications for Genetic Testing in RCC-Related Referral Group 
 
  Test Result  
 All RCC-related 
referral patients 
(n=107) 
N        % 
Any Testing 
 
(n=97) 
N        % 
Positive 
 
 
N        % 
*Negative 
 
 
N        % 
P 
value 
All 107     (100%) 97     (100%) 16     (16%) 81     (84%)  
Testing Indication Met      
ANY RCC-related 
syndrome criteria 
12     (11%) 12     (12%) 7     (58%) 5     (42%) <0.001 
ACMG/NSGC RCC 
Guidelines 
60     (56%) 60     (62%) 7     (12%) 53     (88%) 0.10 
RCC diagnosed ≤ 46 44     (41%) 42     (43%) 5     (12%) 37     (88%) 0.29 
No testing criteria met 29     (27%) 21     (22%) 1     (5%) 20     (95%) 0.18 
Familial RCC 12     (11%) 12     (12%) 1     (8%) 11     (92%) 0.68 
*Negative column includes true VUS results 
testing. In this group, 60 of the 97 patients who had genetic testing (62%) met ACMG/NSGC 
guidelines, making this the most common indication for testing. Of the 9 distinct criteria that make 
up ACMG/NSGC guidelines for RCC, the most commonly met criterion, seen in 67% of the 60 
patients meeting guidelines, was “RCC with clear cell histology AND dx at age <50 OR bilateral or 
multifocal tumors OR ≥1 close relative with clear cell RCC” (13). In bivariate analysis, meeting 
published clinical criteria for an RCC syndrome significantly predicted a positive test result 
(P<0.001), but meeting ACMG/NSGC guidelines, diagnosis ≤ 46, and presence of familial RCC did 
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not.  Twenty-four (24) patients diagnosed at ≤ 46 years had no additional syndromic features or 
family history and none in this group tested positive for a germline mutation. In comparison, 18 
patients diagnosed at ≤ 46 years had either syndromic features and/or a pedigree suggestive of an 
RCC syndrome and 5 of them tested positive for a germline mutation. 
Figure 1 depicts the frequency of the cancerous and non-cancerous features seen in this 
clinic among patients in the RCC-related referral group who tested positive and who tested 
negative. The figure shows that patients who had early onset RCC and positive germline testing had 
additional finding contributing to their risk assessment other than their age of RCC diagnosis. 
Conversely, none of the patients with early onset ccRCC as their sole criterion had a positive 
germline test. 
Figure 1 Frequency of RCC Hereditary Syndrome Features Among RCC-Related Referral Group 
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There were 101 patients in the prostate-related referral group. Genetic testing was ordered 
for 70 patients in this population and a mutation was identified in 7 of them. There were 5 
mutations in the BRCA2 gene and 2 mutations in the ATM gene. The indications for ordering 
genetic testing are summarized in Table 4. The most common indication for ordering genetic 
Table 4  Indications for Genetic Testing in Prostate-Related Referral Group 
 
  Test Result  
 All prostate-
related referral 
patients 
(n=101) 
N           % 
Any 
Testing 
 
(n=70) 
N           % 
Positive 
 
 
N           % 
*Negative 
 
 
N           
% 
P value 
All 101   (100%) 70   
(100%) 
7   (10%) 63   (90%)  
Testing Indication Met      
NCCN Guidelines for 
HBOC 
43   (43%) 37   (53%)  6   (16%) 31   (84%) 0.11 
ACMG/NSGC Prostate  
Cancer Guidelines 
15   (15%) 15   (21%) 1   (7%) 14   (93%) >0.99 
Metastatic prostate 
cancer 
56   (55%) 39   (56%)  4   (10%) 35   (90%) >0.99 
No testing criteria met 23   (23%) 12   (17%) 1   (8%) 11   (92%) >0.99 
Familial PrCa 18   (18%) 16   (23%)  2   (13%) 4    (88%) >0.99 
*Negative column includes true VUS results 
testing was having metastatic prostate cancer (39 of 70, 56%) followed closely by meeting NCCN 
guidelines for HBOC (37 of 70, 53%). ACMG/NSGC guidelines for prostate cancer were also cited 
as an indication for testing in 21% of patients in this group. All 15 men meeting ACMG/NSGC 
guidelines met the same criterion within the guidelines: “aggressive (Gleason>7) prostate cancer 
and ≥2 cases of breast, ovarian, and/or pancreatic cancer in close relatives” (13). Bivariate analysis 
revealed that none of the indications for genetic testing in the prostate-related referral group 
(meeting NCCN criteria for HBOC, meeting ACMG/NSGC guidelines, personal history of 
metastatic prostate cancer, or presence of familial prostate cancer) significantly predicted a positive 
test result. There were 16 men with metastatic prostate cancer as their only indication for genetic 
testing and no germline mutations were identified in this group. In comparison, 23 patients had 
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metastatic prostate cancer in addition to a relevant family history of either prostate, breast, or 
ovarian cancer and 4 were found to have germline mutations.  
Figure 2 shows the frequency of features that suggest a hereditary cancer syndrome for 
patients in the prostate-related referral group. This figure shows that all men with aggressive, 
metastatic prostate, in the absence of a relevant family history or additional indication for genetic 
testing, had negative germline testing. Of note, a single patient lacking family history may be seen 
in the positive section, however this patient had a known familial mutation (Appendix A).  
 
Figure 2  Frequency of Hereditary Syndrome Features Related to Prostate Cancer Among Prostate-  
Related Referral Group 
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DISCUSSION 
This is the first study to describe clinical features and genetic testing outcomes of a patient 
cohort referred to a GU Genetics Clinic that is following current guidelines for germline genetic 
testing. Patients were referred to genetic counseling in this setting primarily for evaluation of 
hereditary cancer syndromes related to RCC and prostate cancer. A minority group of patients were 
referred for genetic evaluation of other GU cancer types, including UTUC, bladder cancer, and 
testicular cancer. A shift in referrals to this GU Genetics Clinic was seen over the course of the 
collection period. There were significant changes in published recommendations for genetic 
evaluation of men with prostate cancer during the time that this patient population was assessed. 
Most notably, a study published in August, 2016 recommended genetic testing for all men with 
metastatic prostate cancer, regardless of age of diagnosis or family history (3). This significant 
change in guidelines likely contributed to the shifting referral pattern noted between 2014 and 2017.  
In the RCC population, three overarching indications drove genetic testing for patients with an 
RCC-related referral: meeting published clinical diagnostic criteria for an RCC-related hereditary 
cancer syndrome, meeting ACMG/NSGC guidelines for RCC, and being diagnosed with RCC ≤ 46 
years old. Meeting ACMG/NSGC guidelines was the most commonly indicated reason for ordering 
genetic testing, likely due to the nature of these guidelines being comprised of multiple individual 
indications for testing. For example, a patient with bilateral ccRCC, a patient with papillary type II 
RCC, and a patient with chromophobe RCC would all meet these guidelines for different reasons. 
However, meeting ACMG/NSGC guidelines did not predict positive germline testing for an RCC 
syndrome (P=0.10). It is important to highlight, again, that these guidelines are not intended to 
determine when a clinician should order genetic testing, but only when a patient should be referred 
for genetic evaluation. These guidelines aim to catch all individuals who may be at risk for an RCC-
related hereditary cancer syndrome, therefore valuing the sensitivity of the guidelines over the 
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specificity. This contributes to the failure to show a significant relationship between meeting these 
guidelines and testing positive. Furthermore, it underscores the value of the genetic counseling 
process to identify the patients meeting these guidelines who warrant genetic testing. 
In our patient population, early onset RCC was not a predictor of positive germline testing. This 
is in contrast to the findings of previous studies suggesting that early onset RCC is suggestive of 
hereditary RCC syndromes (4, 15). In fact, 88% of patients with early onset RCC in our cohort did 
not have an identifiable mutation and the 12% who tested positive for a germline mutation had 
additional features that were suggestive of the syndrome they tested positive for, including non-
cancerous features or abnormal immunohistochemistry (IHC) staining (Appendix A). Our study 
also identified 22 patients with very young RCC (defined using a previously published 2.5% 
threshold of diagnosis at ≤36 years) who received multi-gene panel testing (4). Again, in the 
absence of additional suggestive features, none of them tested positive, despite an expected 
inherited component due to their very early age of RCC diagnosis. Among hereditary RCC 
syndromes, VHL disease is thought to have the earliest median age of RCC onset at 38.9 to 44 
years old (18, 19). Similarly, the median age of onset for HLRCC is 44 years old (20). However, 
even VHL disease and HLRCC do not adequately account for the very young RCC population, 
especially when these patients present without syndromic features or family history. It is likely that 
there are unidentified genes or genetic factors that are contributing to these very young, isolated 
RCC diagnoses and current testing strategies are ineffective at identifying them. 
The only indication in our cohort that significantly predicted positive germline testing was 
meeting published clinical criteria for an RCC-related syndrome. This is perhaps not surprising 
given the strict nature of published guidelines. Among the 16 patients who tested positive in the 
RCC-related referral group, 3 had testing for known familial mutations. The additional 13 patients 
either met published clinical diagnostic criteria for an RCC-related syndrome or met ACMG/NSGC 
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guidelines. In Figure 1, the left portion of the heat map, corresponding to patients testing positive, 
shows the presence of multiple cancerous and non-cancerous features, even in patients with early 
onset RCC. In contrast, the right portion of the map, corresponding to patients with negative genetic 
testing, shows large areas lacking coloration, highlighting all of the patients with early onset RCC 
as their sole indication for testing. No positive patient in this population was identified solely by age 
at diagnosis, again raising the question of whether very young RCC diagnoses, in the absence of 
additional indications for testing, are described by any of the known RCC-related syndromes or 
genes. 
In a clinical setting, early onset RCC coupled with a rare tumor histology or syndromic features 
should warrant genetic testing, even if the patient does not meet strict clinical diagnostic criteria for 
the suspected RCC-related syndrome. Of the 16 patients who tested positive in our RCC population, 
5 of them did not meet strict clinical criteria for the syndrome they tested positive for, although they 
did have non-cancerous findings suggestive of the syndrome (Appendix A). Some RCC syndromes, 
such as BHD, may require updated clinical diagnostic criteria since it is now known that 
characteristic renal tumors or pulmonary findings may sometimes be the presenting features of this 
condition, rather than dermatologic findings (21).  
Genetic testing may still be warranted for individuals with only early onset RCC, but pretest 
counseling, including a thorough risk assessment and discussion of the limitations of genetic 
testing, becomes even more critical in these cases. Additional research on the value of performing 
multi-gene panel testing on patients with very early onset RCC in the absence of accompanying 
syndromic features or positive pedigree must be performed to determine whether this approach is 
valid. Gene hunting studies incorporating whole exome sequencing are also warranted for this 
patient population due to our perceived lack of knowledge on the genetic contributions to RCC.  
16  
  
Similar to the RCC-related referral group, three general indications for genetic testing were 
evaluated in the prostate-related referral group: meeting NCCN guidelines for Breast and Ovarian 
Cancer syndrome, meeting ACMG/NSGC guidelines for prostate cancer, and presence of metastatic 
prostate cancer. The most common indication for ordering genetic testing was having metastatic 
prostate cancer (39 of 70 patients tested, 56%), followed closely by meeting NCCN guidelines for 
HBOC (37 of 70 patients tested, 53%). All patients were seen prior to the inclusion of metastatic 
prostate cancer as a criterion for meeting NCCN guidelines for HBOC. Additionally, some men in 
this study were seen before metastatic prostate cancer was considered an independent indication to 
perform genetic testing in the absence of a family history of HBOC-associated cancers. This 
contributed to the lower number of individuals who pursued genetic testing in this group. 
Retrospectively, it was identified that 56 men had metastatic prostate cancer and therefore meet 
current guidelines for genetic testing. However, that was not, by itself, an indication for testing in 
all 56 men at the time of their genetic counseling consultation.  
In the prostate-related referral group, no significant relationships between indication for genetic 
testing and positive genetic test results were identified. The small number of patients who tested 
positive in this group was a limiting factor of the analysis. Of the 7 prostate-related patients who 
tested positive, 6 of them met NCCN guidelines for HBOC testing. A single patient was identified 
to have a BRCA2 mutation without meeting any guidelines for genetic testing. This patient desired 
genetic testing due to the presence of familial, late-onset prostate cancer but no other family history 
of cancer. No patient in this study had a germline mutation identified due to the presence of 
metastatic prostate cancer alone.  
It is important to note, however, that 25 of the 70 men who underwent genetic testing in the 
prostate-related referral group had single syndrome testing for HBOC only (BRCA1, BRCA2). 
Single syndrome testing may have been the only testing indicated for many patients at the time of 
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their genetic counseling consultation. It has been suggested that germline mutations in 16 different 
DDR genes can contribute to metastatic prostate cancer, supporting the use of multi-gene panel 
testing in this population (3). Our study only identified mutations in BRCA2 and ATM within the 
prostate group, which may reflect the higher proportion of hereditary prostate cancers attributed to 
these two genes but it may also reflect the limited genetic analysis in our population. 
Thorough pretest counseling is incredibly valuable in this group, similar to the RCC-related 
group. Multi-gene panel testing should be considered for men with metastatic prostate cancer but 
should include a discussion of the likely reduced chance of testing positive if the patient does not 
have any additional family history of HBOC-associated cancers. The recent Philadelphia Prostate 
Cancer Consensus Conference (2017) revealed a moderate consensus (50-74% consensus) among 
participants to use multi-gene panel testing for all men with metastatic castration-resistant prostate 
cancer, regardless of family history, but a stronger consensus (≥75% consensus) to test only BRCA1 
and BRCA2 in the same scenario, which highlights the varying opinions of experts in the field 
regarding genetic testing in this population (22).  
Finally, this study identified that a combination of testing strategies, including both single 
syndrome testing and multi-gene panel testing, was utilized in this clinic. Overall, a GU cancer 
population may be a very good fit for this combination approach to genetic testing in part because 
RCC syndromes are characteristically different from one another. A patient with BHD, for example, 
would likely have a tumor histology or non-cancerous features that are very descriptive of BHD and 
also very distinct from another RCC syndrome. Single syndrome testing is valuable in an RCC 
population because it is possible to distinguish between RCC syndromes based on clinical findings. 
Single syndrome testing, when applicable, also comes with the added benefit of a low VUS rate 
(less than 1% in this study). However, a GU cancer population will also include many patients with 
prostate cancer. It is much more challenging to differentiate between hereditary syndromes related 
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to prostate cancer. This is because the features that are suggestive of these syndromes are primarily 
family history feaures that may be seen in multiple prostate-related syndromes or even in people 
with no hereditary cancer syndrome at all. In Figure 2, the patients in the positive group are 
suspicious for a syndrome because they have multiple features suggesting a syndrome. However, it 
would be hard to distinguish the BRCA2 positive patients from the ATM positive ones based on the 
family history features listed.  
Single syndrome testing has drawbacks, primarily that a clinician cannot rule out the presence 
of mutations in the genes that were not tested. While this limitation should be considered when 
chooseing the type of genetic testing to order, the impact of a VUS result on a patient should be 
considered as well. One study of patient perceptions of VUS results in an oncology setting reported 
that 29% of patients receiving VUS results recalled their genetic testing being pathogenic, and over 
half of the 29% underwent potentially unnecessrary prophylactic surgery as a result of their 
misunderstanding (23). This also suggests that genetic test results, especially VUSs, may be 
misunderstood by patients’ other physicians, such as their surgeons. A study of pediatric 
oncologists found that only 27% were confident in interpreting and discussing germline genetic 
testing with patients (24). Given these concerns, it is important to use a risk assessment and pretest 
counseling to determine the best testing strategy for each patient. In a GU setting especially, there is 
a place for both multi-gene panel testing and single syndrome testing when a thorough three 
generation pedigree and evaluation of cancerous and non-cancerous features is used to guide risk 
assessment. 
Small sample size limits the applicability of this study to a larger population. The purpose of 
this paper was to describe the overall population seen in a GU Genetics Clinic, however additional 
studies focusing on RCC and prostate cancer populations individually are warranted in order to 
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increase sample size. Specifically, this study supports a need to further evaluate genetic testing 
outcomes in patients with very young RCC diagnoses.  
The evaluation of clinical data introduces limitations as well. Not all patients in the RCC-related 
referral group and prostate-related referral group received the same genetic test since the type of 
testing was decided upon by the patient and the genetic counselor as part of the genetic counseling 
session. Additionally, multi-gene panels changed and expanded over the course of this study 
(Appendix B). Clinical information is also limited by the ability of the patients to accurately self-
report family history, including ages of cancer diagnoses and, specifically in the case of an RCC-
related evaluation, presence or absence of syndromic features in family members. However, this 
study provided an in-depth evaluation of patients’ personal and family history and assessment of 
specific syndromes. The clinical perspective provided by this study design was invaluable as it 
allowed detailed analysis of the reasons for genetic testing in a GU cancer population, which has 
not been commented on previously. 
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CONCLUSION 
This study described a GU Genetics Clinic that evaluated patients for primarily RCC and 
prostate-related hereditary cancer syndromes. Pretest counseling for genetic testing in this 
population is critical considering the varying indications that are present. Patients seen for 
evaluation of RCC-related syndromes should be assessed for non-cancerous features and family 
history of RCC. Meeting clinical diagnostic criteria for an RCC-related syndrome predicts for 
positive germline test results. Genetic testing should be considered for patients with early onset 
RCC and syndromic features, even in the absence of meeting established clinical diagnostic criteria. 
Individuals with early onset RCC and no additional features in their risk assessment should be 
counseled on the limitations of genetic testing for this indication and further assessment of the 
genetic contributions to RCC is required. Prostate cancer patients may benefit from multi-gene 
panel testing based on previous studies but will also benefit from pretest counseling on the reduced 
likelihood to test positive if they lack a family history of relevant cancers. Genetic testing in a GU 
population should incorporate both single syndrome testing and multi-gene panel testing to 
accommodate the varying levels of risk assessment. 
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APPENDIX   
Appendix A  Clinical Features of Patients with Positive Germline Test Results  
  
Age  
at  
Dx 
Sex Mutation Test Type Features in Patient Syndrome 
Criteria 
ACMG/ 
NSGC 
Guidelines 
RCC 
Dx ≤ 
46 
Familial 
RCC 
mPrCa Familial 
PrCa 
Features in Relatives1 
RCC-Related Referral Group 
29  M  FH  Single site  Tubulopapillary RCC  x  x    x  NA  x 
  
NA  F  FH  Single site    x  x  NA  x  NA  x 
  
NA  F  FH  Single site  Uterine leiomyomas  HLRCC  x  NA  x  NA  x 
Uterine leiomyomas  
40  F  FH  Single 
syndrome- 
HLRCC  
Papillary type II RCC 
Uterine leiomyomas  
x     x  NA  x 
  
NA  M  FLCN  Single 
syndrome- 
BHD  
Fibrofolliculoma  
Spontaneous pneumothorax  
BHD  x  NA  x  NA  x  
  
47  M  FH  Single 
syndrome- 
HLRCC  
Papillary type II RCC  x   x  x  NA  x 
  
49  F  FLCN  Multi-
gene 
panel2   
Bilateral ccRCC  
Spontaneous pneumothorax  
x    x        
  
NA  F  VHL  Single 
syndrome-  
VHL  
CNS hemangioblastomas 
Neuroendocrine tumor of 
pancreas  
VHL  x  NA  x  NA  x 
Reported VHL (no proof of 
testing available)  
NA  F  VHL  Single 
syndrome-  
VHL  
Single 
syndrome- 
HBOC  
Hemangioblastomas  VHL 
HBOC  
x  NA    NA  x  
Reported VHL (no proof of 
testing available)  
60  M  BAP1  Multi-
gene panel  
Bladder cancer, dx 60 
ccRCC dx 67 Hx of 
polyposis  
Melanoma dx 67  
Lymphoma dx 67  
x   x  x  NA  x  
  
25  M  SDHB  Multi-
gene panel  
Oncocytoma type RCC dx 25 
Loss of SDHB on IHC  
x    x  NA  x  
  
NA  F  FLCN  Single 
syndrome- 
BHD  
Fibrofolliculomas  BHD  x  NA  x  NA  x  
Pneumothoraces,  
fibrofolliculomas, pulmonary 
cysts  
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57  F  FLCN  Multi-
gene panel  
RCC with mixed pathology 
(oncocytoma and papillary type) 
dx 57  
Angiofibromas  
Pulmonary cysts  
Bilateral renal tumors  
BHD   x  x  NA  x  
Spontaneous pneumothoraces  
39  F  TP53  Multi-
gene panel  
ccRCC dx 39  
Pancreatic cancer dx 52  
HBOC    x  NA  x  
LFS spectrum cancers  
NA  F  VHL  Single 
syndrome-  
VHL  
Hemangioblastomas   VHL 
HBOC  
x  NA  x  NA  x  
VHL (clinical and molecular dx) 
41  M  FLCN  Single 
syndrome- 
BHD  
Chromophobe RCC dx 41 
Pulmonary cysts  
x     x  NA  x  
  
Prostate-Related Referral Group 
 66  M  BRCA2  Single 
site- 
familial 
mutation  
Aggressive PrCa3  HBOC   NA  x    x  
 Ovarian cancer 
47  M  BRCA2  Single 
site- 
familial 
mutation  
Aggressive PrCa HBOC  x  NA  x   x  
Three breast cancer primaries 
68  M  BRCA2  Single 
syndrome- 
HBOC  
  HBOC  x  NA  x    x  
 Breast, ovarian cancer 
53  M  BRCA2  Single 
syndrome- 
HBOC  
Aggressive PrCa  HBOC  x  NA  x    x  
 Breast cancer dx 41, 43 
67  M  ATM  Single 
syndrome- 
HBOC  
+ ATM  
Aggressive PrCa  HBOC  x  NA  x  x  x  
 Breast cancer dx 31 
55  M  BRCA2  Multi-
gene panel  
Aggressive PrCa  
  
x  x  NA  x  x   
  
50  M  ATM  Multi-
gene panel  
  HBOC  x  NA  x  NA   
 Familial breast cancer 
Other Referrals 
56  F  MSH2  Single 
syndrome- 
HNPCC  
UTUC dx 56  
MSI-H, loss of MSH2, PMS2 on 
IHC  
x   NA  x  NA  x  
  
67  F  FH  Single 
syndrome 
HNPCC, 
Multi-
gene panel  
UTUC dx 67  
MSI-H, loss of MSH2, PMS2 on  
IHC  
Paraganglioma of the bladder  
Adrenal adenoma  
x  x  NA  x  NA  x  
  
45  F  BRCA1  Multi-
gene panel  
Breast cancer dx 45, 55 
UTUC dx 70  
Uterine cancer dx 70  
HBOC  x  NA  x  NA  x  
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54  F  MSH2  Multi-
gene panel  
UTUC dx 54  
MSI-H, loss of MSH2, PMS2 on 
IHC  
HBOC   NA  x  NA  x  
  
Appendix A  
Abbrieviations- Dx: diagnosis; mPrCa: metastatic prostate cancer; NA: not applicable; CNS: central 
nervous system; HLRCC: hereditary leiomyomatosis and RCC syndrome; BHD: Birt Hogg Dube 
syndrome; VHL: von Hippel Lindau disease; HBOC: hereditary breast and ovarian cancer 
syndrome; LFS: Li Fraumeni syndrome; UTUC: upper tract urothelial carcinoma; MSH-H: 
microsatellite high; IHC: immunohistochemistry staining  
1 “Relatives” includes first, second, and third degree relatives only  
2 See Appendix B for the genes included in all multi-gene panels  
3 Aggressive prostate cancer defined by Gleason score ≥ 7 
 
Appendix B Genes Included in Multi-Gene Panel Tests  
  
Study ID  Panel Type  No. Genes 
on Panel  
Genes Included  
46, 118, 119  RCC panel  19  BAP1, EPCAM, FH, FLCN, MET, MITF, 
MLH1, MSH2, MSH6, PMS2, PTEN, 
SDHA, SDHB, SDHC, SDHD, TP53, TSC1, 
TSC2, VHL  
97  Pan-cancer panel  49  APC, ATM, BARD1, BMPR1A, BRCA1, 
BRCA2, BRIP, CDH1, CDK, CDKN2A, 
CHEK2, EPCAM, GREM1, MLH1, MSH2, 
MSH6, MUTYH, NBN, PALB2, POLD1, 
POLE, PMS2, PTEN, RAD51C, RAD51D,  
SMAD4, STK11, TP53, BAP1, FH, FLCN, 
MAX, MEN1, MITF, MET, MRE11A, NF1, 
RAD50, RET, SDHA, SDHAF2, SDHB, 
SDHC, SDHD, SMARCA4, TMEM127, 
TSC1, TSC2, VHL  
110  PGL/PCC1  
syndrome panel  
5   SDHA, SDHB, SDHC, SDHD, SDHAF2  
134  Prostate panel  12  ATM, BRCA1, BRCA2, CHEK2, EPCAM, 
HOXB13, MLH1, MSH2, MSH6, NBN,  
PMS2, TP53  
136  PGL/PCC  
syndrome panel  
14   FH, MAX, MEN1, NF1, RET, SDHA, 
SDHAF2, SDHB, SDHC, SDHD, 
TMEM127, VHL, EGLN1, KIF1B  
143, 215  Custom panel  12  BRCA1, BRCA2, ATM, PALB2, CHEK2, 
EPCAM, MLH1, MSH2, MSH6, PMS2,  
TP53, PTEN  
24  
  
157  Prostate panel  14   ATM, BRCA1, BRCA2, CHEK2, EPCAM, 
HOXB13, MLH1, MSH2, MSH6, NBN,  
PALB2, PMS2, RAD51D, TP53  
Appendix B  
1PGL/PCC: paraganglioma/ pheochromocytoma 
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